33.02
+1.09(+3.41%)
Currency In USD
| Previous Close | 31.93 |
| Open | 32 |
| Day High | 33.39 |
| Day Low | 32 |
| 52-Week High | 62.53 |
| 52-Week Low | 24.1 |
| Volume | 621,646 |
| Average Volume | 792,016 |
| Market Cap | 3.09B |
| PE | -8.69 |
| EPS | -3.8 |
| Moving Average 50 Days | 31.17 |
| Moving Average 200 Days | 41.41 |
| Change | 1.09 |
If you invested $1000 in Crinetics Pharmaceuticals, Inc. (CRNX) since IPO date, it would be worth $1,347.21 as of July 14, 2025 at a share price of $33.02. Whereas If you bought $1000 worth of Crinetics Pharmaceuticals, Inc. (CRNX) shares 5 years ago, it would be worth $2,170.94 as of July 14, 2025 at a share price of $33.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
GlobeNewswire Inc.
Yesterday at 9:45 PM GMT
Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies Additional PALSONIFY presentations demonstrate reductions in patient-reported symptom
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
GlobeNewswire Inc.
Jul 11, 2025 12:00 PM GMT
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jul 10, 2025 8:28 PM GMT
SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggrega